Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02950766
Title A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Patrick Ott, MD
Indications

renal cell carcinoma

Therapies

Ipilimumab + NeoVax

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field